Home Mechanical Ventilation (HMV) is the proposed treatment therapy in patients with COPD and chronic respiratory failure with hypercapnia. A descriptive observational study of HMV has been carried in COPD patients from 2019 to 2022. Epidemiological and demographic data, COPD phenotype and pCO2, have been collected before and after the establishment of the HMV. The data has been compiled through the platform AirView ®Resmed. The software SAP was used to assemble data for admissions, emergency consultations and deaths and their relationship with the pressures used has been analysed: 68 patients were included, 50 were males (72%), median age was 71 years [55-86]. The predominant phenotype was emphysema (60.3%) and average airflow obstruction was 42.3% [15-117%]. ST mode was used predominantly with Lumis 150 ®Resmed device. The average IPAP was 17.04 cmH2O [10-24 cmH2O] and PEEP 8.91 cmH2O [5-13 cmH2O] with no differences between phenotypes. Average compliance was 7.66 [1.17-13.46 hours] and leakage 26.65 L/min [0-116]. There was a significant improvement in pCO2 in 52.4% patients. A significant relationship between the need for higher IPAP and PEEP was found with the number of emergency room visits (CC 0.35) and hospital admissions (CC 0.48).

In conclusion, using higher pressures has been related to a significant gas exchange  improvement and to a greater number of admissions and visits to the ER.